Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

BACKGROUND: The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with alectinib versus crizotinib. Here, we present detailed cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, Camidge, D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290889/
https://www.ncbi.nlm.nih.gov/pubmed/30215676
http://dx.doi.org/10.1093/annonc/mdy405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290889/
https://www.ncbi.nlm.nih.gov/pubmed/30215676
http://dx.doi.org/10.1093/annonc/mdy405

Ejemplares similares